AMENDMENTS TO CLAIMS

Claim 1. (Cancelled).

Claim 2. (Currently Amended) The method as defined in Claim 34 wherein the [[A]] compound ~~having~~ employed has the structure



Claims 3 to 4. (Cancelled).

Claim 5. (Currently Amended) The ~~compound~~ method as defined in Claim ~~1~~ 34 where in the compound employed ~~wherein~~ $(CH_2)x$ is alkylene, alkenylene, allenyl, or alkynylene.

Claims 6 to 9. (Cancelled).

Claim 10. (Currently Amended) The ~~compound~~ method as defined in Claim ~~1~~ 34 ~~wherein $R^{2a}$ is alkoxy or H,~~ where in the compound employed

$(CH_2)_x$ is $CH_2$, $(CH_2)_2$, $(CH_2)_3$, or $-\overset{CH_3}{\overset{|}{C}}(CH_3)-$, $(CH_2)_m$ is $CH_2$, or $-\overset{R_a}{\overset{|}{C}}H-$ (where $R_a$ is alkyl or alkenyl), $(CH_2)_n$ is $CH_2$, $R^1$ is lower alkyl, ~~preferably $CH_3$,~~ $R^2$ is H, $R^{2a}$ is H, $R^4$ is H, ~~X is CH,~~ and $R^3$ is arylalkyloxycarbonyl, ~~arylheteroarylalkyl, aryloxyarylalkyl, arylalkyl,~~ aryloxycarbonyl, haloaryl-oxycarbonyl, alkoxyaryloxycarbonyl, alkylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl, heteroaryloxycarbonyl, ~~aryloxyarylcarbonyl,~~ arylalkenyloxycarbonyl,

cycloalkylaryloxycarbonyl, ~~arylalkylarylcarbonyl, heteroaryl-heteroarylalkyl,~~ cycloalkyloxyaryloxycarbonyl, ~~heteroaryl-heteroarylcarbonyl,~~ alkyloxyaryloxycarbonyl, arylalkylsulfonyl, arylalkenylsulfonyl, ~~alkoxyarylalkyl,~~ arylthiocarbonyl, cycloheteroalkylalkyloxycarbonyl, cycloheteroalkyloxycarbonyl, or polyhaloalkylaryloxycarbonyl, which may be optionally substituted.

Claims 11 to 15. (Cancelled).

Claim 16. (Currently Amended) The ~~compound~~ method as defined in Claim ~~1 having~~ 34 wherein the compound employed has the structure

















where ~~$R^3$~~ [[=]]






O
Cl
O
CF3
O
CH3


O
OCH3
Cl
O
F


O
S
N
S
O


O
F
S
Cl
O
OCH3
OCH3


N
H
Cl
O
Cl
O
F3C


O
NO2
CF3
O
Cl
O
CF3


O
O2N
H
N
O
H3C
CH3
O
Ph
O
Br



















where ~~$R^3$~~ [[=]]













- 8 -


































Ph
N
O
CH3
O
O
N
CO2H
R3c
where R36 [[=]]


(S) CH3
(R) CH3
H3C
CH3
O
OH
(s)
(R)
(R)
(R)
(R)


Ph
N
O
CH3
O
O
N
CO2H
O
O


Ph
N
O
CH3
O
OCH3
O
O
N
CO2H
Cl
Cl


Ph
N
O
CH3
O
O
N
CO2H
OCH3
OCHF2


Ph
N
O
CH3
O
O
N
CO2H
OCHF2





where $R^{3d}$ [[=]]







































where $R^{3d}$ [[=]]


















Br
CH3
F
Cl
Br
OCF3


F
Cl
Br
F
F
CH3
F
Cl


CH3
CH3
CH3
CH3
Cl
F
F
F
CH3
Cl
F


SCH3
CH3
N
CF3


H3C
CH3
CH3
CH3
CH3
CH3
CH3


Cl
CH3
CH3
CH3
CH3


CH3
O
CH3


Cl
Cl
N
N
S
CF3
F
OCH3
CH3
















Ph
N
O
O
CH3
R3e
N
O
OH

where $R^{3e}$ [[=]]


F
F
O


CH3
CH3
S
S
S
CH3
S
NO2
S
CH3


O
OCH3
CH3
OCH3
Cl
CH3
CH3


CH3
CH3
F
SCH3
CH3
CH3


CH3
CH3
Cl
CH3
OCH3
O
O


CH3
O
CH3
S
OCH3
F


Cl
Cl
O
CH3
O
CH3
CH3










where R3e [[=]]























where $R^{3f}$ [[=]]







where $R^{3f}$ [[=]]









where $R^{3g}$ [[=]]










Ph
N
O
CH3
O
N
CO2H
O2S
R3g

where ~~$R^{3g}$~~ [[=]]


CH3
H3C
CH3
Cl


CH3
H3C
Cl
Cl
Cl
O
NO2


O
CF3
CH3
F
F


Cl
Cl
F
Cl
Cl
Cl
Cl
Cl


CH3
OCF3


Ph
N
O
CH3
O
N
N
CO2H
O





where $R^3$ [[=]]









where $R^3$ [[=]]




where R3 [[=]]








where R3h [[=]]







where ~~$R^{3h}$~~ [[=]]

















(racemate)



, where $R^a$ [[=]] ~~(±) Me , (±) n-Bu ,~~




~~where $R^a$ [[=]] (±) Et, (±) i Bu,~~





























































































Claim 17. (Cancelled).

Claim 18. (Currently Amended) The ~~compound~~ method as defined in Claim 34 ~~1 having~~ wherein the compound employed has the structure























[,] .

Claim 19. (Cancelled).

Claim 20. (Currently Amended) The ~~compound~~ method as defined in Claim ~~1~~ 34 ~~having~~ wherein the compound employed has the structure






















































































































































Claims 21 to 33. (Cancelled).

Claim 34. (Currently Amended) A method for lowering blood glucose levels or for treating diabetes, or for treating an early malignant disease, a malignant disease or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound ~~as defined in Claim 1~~ which has the structure




wherein x is 1,2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

$R^1$ is H or lower alkyl;

X is CH or N; with the proviso that where Z is O then Q is N or A is S or X is N;

$R^2$ is H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^3$ is aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylalkenyloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxycarbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, arylalkoxycarbonylheteroarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl or polyhaloalkylaryloxycarbonyl;

Y is $CO_2R^4$ were $R^4$ is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $P(O)(OR^{4a})R^5$ here $R^{4a}$ is H or a prodrug ester, $R^5$ is alkyl or aryl or a phosphonic acid of the structure $P(O)(OR^{4a})_2$ where $R^{4a}$ is H or a prodrug ester;

or stereoisomers thereof, a prodrug ester thereof, and a pharmaceutically acceptable salt thereof.

Claims 35 and 36. (Cancelled).

Claim 37. (Currently Amended) A pharmaceutical combination comprising a compound which has the structure



wherein x is 1,2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

$R^1$ is H or lower alkyl;

X is CH or N;

$R^2$ is H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^3$ is aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylalkenyloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxycarbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, arylalkoxycarbonylheteroarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl or polyhaloalkylaryloxycarbonyl;

Y is $CO_2R^4$ were $R^4$ is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $P(O)(OR^{4a})R^5$ here $R^{4a}$ is H or a prodrug ester, $R^5$ is alkyl or aryl or a phosphonic acid of the structure $P(O)(OR^{4a})_2$ where $R^{4a}$ is H or a prodrug ester;

or stereoisomers thereof, a prodrug ester thereof, or a pharmaceutically acceptable salt thereof ~~as defined in Claim 1~~ and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent which is other than a diuretic, a platelet aggregation inhibitor, and/or an antiosteoporosis agent.

Claim 38. (Cancelled)

Claim 39. (Currently Amended) The combination as defined in Claim ~~38~~ 37 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPARα agonist, a PPAR γ agonist, a PPAR α/γ dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an aP2 inhibitor, an insulin sensitizer, a glucagon-like peptide-I (GLP-I), insulin and/or a meglitinide; the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine)

reuptake inhibitor, a thyroid receptor agonist, an aP2 inhibitor and/or an anorectic agent; the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor; the antihypertensive agent is an ACE inhibitor, angiotensin II receptor antagonist, NEP/ACE inhibitor, calcium channel blocker and/or β-adrenergic blocker.

40. (Currently Amended) The combination as defined in Claim 39 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, GI-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98 and/or NVP-DPP-728A; the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol; the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, itavastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, niacin and/or LY295427; the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEP/ACE inhibitor which is omapatrilat, [S[(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat) or CGS 30440;

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;

amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or clonidine HCl; the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban.

Claims 41 to 49. (Cancelled).

Claim 50. (Currently Amended) A method for treating insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, Syndrome X, dysmetabolic syndrome, inflammation, diabetic complications, impaired glucose homeostasis, impaired glucose tolerance, hypertriglyceridemia, ~~or~~ atherosclerosis, or for treating irritable bowel syndrome, Crohn's disease, gastric ulceritis or osteroporosis, or psoriasis, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim ~~43~~ 37.

Claim 55. (New) A pharmaceutical combination comprising a compound which has the structure



wherein x is 1,2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

$R^1$ is H or lower alkyl;

X is CH or N;

$R^2$ is H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^{2a}$, $R^{2b}$ and $R^{2c}$ are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

$R^3$ is aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylalkenyloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxycarbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, arylalkoxycarbonylheteroarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl or polyhaloalkylaryloxycarbonyl;

Y is $CO_2R^4$ where $R^4$ is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $P(O)(OR^{4a})R^5$ where $R^{4a}$ is H or a prodrug ester, $R^5$ is alkyl or aryl or a phosphonic acid of the structure $P(O)(OR^{4a})_2$ where $R^{4a}$ is H or a prodrug ester;

or stereoisomers thereof, a prodrug ester thereof, or a pharmaceutically acceptable salt thereof, and an antihypertensive agent which is a diuretic.

Claim 56. (New) The combination as defined in Claim 55 wherein the diuretic is hydrochlorothiazide, torasemide, furosemide, spironolactone or indapamide.